Maria Grazia Spillantini

List of Publications by Year
in descending order

96 papers	23,431 citations	30070 54 h-index	43889 91 g-index
98 all docs	98 docs citations	98 times ranked	20114 citing authors

#	Article	IF	Citations
1	Î±-Synuclein in Lewy bodies. Nature, 1997, 388, 839-840.	27.8	7,181
2	A Century of Alzheimer's Disease. Science, 2006, 314, 777-781.	12.6	1,798
3	Filamentous Î±-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neuroscience Letters, 1998, 251, 205-208.	2.1	941
4	100 years of Lewy pathology. Nature Reviews Neurology, 2013, 9, 13-24.	10.1	939
5	Identification of two distinct synucleins from human brain. FEBS Letters, 1994, 345, 27-32.	2.8	922
6	Tau pathology and neurodegeneration. Lancet Neurology, The, 2013, 12, 609-622.	10.2	893
7	Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nature Genetics, 2005, 37, 806-808.	21.4	752
8	Tau protein pathology in neurodegenerative diseases. Trends in Neurosciences, 1998, 21, 428-433.	8.6	652
9	Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein. Journal of Neuroscience, 2002, 22, 9340-9351.	3.6	643
10	The Î±â€Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy. Annals of the New York Academy of Sciences, 2000, 920, 16-27.	3.8	437
11	Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17: A New Group of Tauopathies. Brain Pathology, 1998, 8, 387-402.	4.1	396
12	Frontotemporal Dementia and Corticobasal Degeneration in a Family with a P301S Mutation in Tau. Journal of Neuropathology and Experimental Neurology, 1999, 58, 667-677.	1.7	381
13	Synthetic filaments assembled from C-terminally truncated Î±-synuclein. FEBS Letters, 1998, 436, 309-312.	2.8	373
14	The Synucleinopathies: Twenty Years On. Journal of Parkinson's Disease, 2017, 7, S51-S69.	2.8	350
15	Î±â€Synuclein metabolism and aggregation is linked to ubiquitinâ€independent degradation by the proteasome. FEBS Letters, 2001, 509, 22-26.	2.8	326
16	Ubiquitination of Î±-Synuclein in Lewy Bodies Is a Pathological Event Not Associated with Impairment of Proteasome Function. Journal of Biological Chemistry, 2003, 278, 44405-44411.	3.4	325
17	Proteasomal degradation of tau protein. Journal of Neurochemistry, 2002, 83, 176-185.	3.9	302
18	Pathological Changes in Dopaminergic Nerve Cells of the Substantia Nigra and Olfactory Bulb in Mice Transgenic for Truncated Human Î±-Synuclein(1â€“120): Implications for Lewy Body Disorders. Journal of Neuroscience, 2006, 26, 3942-3950.	3.6	302

#	Article	IF	Citations
19	Tau Mutations Cause Frontotemporal Dementias. Neuron, 1998, 21, 955-958.	8.1	294
20	Filamentous nerve cell inclusions in neurodegenerative diseases. Current Opinion in Neurobiology, 1998, 8, 619-632.	4.2	247
21	SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinsonâ€™s disease. Brain, 2010, 133, 2032-2044.	7.6	236
22	Hereditary Frontotemporal Dementia Caused by Tau Gene Mutations. Brain Pathology, 2007, 17, 63-73.	4.1	182
23	Induction of Inflammatory Mediators and Microglial Activation in Mice Transgenic for Mutant Human P301S Tau Protein. American Journal of Pathology, 2004, 165, 1643-1652.	3.8	180
24	Interaction of tau protein with the dynactin complex. EMBO Journal, 2007, 26, 4546-4554.	7.8	171
25	Atypical, non-standard functions of the microtubule associated Tau protein. Acta Neuropathologica Communications, 2017, 5, 91.	5.2	157
26	Propagation of Tau aggregates. Molecular Brain, 2017, 10, 18.	2.6	154
27	TauGene Mutation K257T Causes a Tauopathy Similar to Pick's Disease. Journal of Neuropathology and Experimental Neurology, 2000, 59, 990-1001.	1.7	145
28	A noveltau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Annals of Neurology, 2000, 48, 939-943.	5.3	136
29	Pick's disease associated with the novel Tau gene mutation K369I. Annals of Neurology, 2001, 50, 503-513.	5.3	128
30	Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimerâ€™s disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2000, 1502, 110-121.	3.8	127
31	Frontotemporal Dementia: Implications for Understanding Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006254-a006254.	6.2	127
32	Synaptic failure and Î±â€synuclein. Movement Disorders, 2016, 31, 169-177.	3.9	126
33	Living Neurons with Tau Filaments Aberrantly Expose Phosphatidylserine and Are Phagocytosed by Microglia. Cell Reports, 2018, 24, 1939-1948.e4.	6.4	118
34	Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients withMAPTmutations. Brain, 2015, 138, 3345-3359.	7.6	116
35	Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. Brain, 2018, 141, 521-534.	7.6	114
36	Analysis of Tau Phosphorylation and Truncation in a Mouse Model of Human Tauopathy. American Journal of Pathology, 2008, 172, 123-131.	3.8	113

#	Article	IF	Citations
37	A novel mutation at position +12 in the intron following Exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto). Annals of Neurology, 2000, 47, 422-429.	5.3	109
38	Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: Effects on axonal viability. Neurobiology of Aging, 2011, 32, 419-433.	3.1	108
39	Pathogenesis of the Tauopathies. Journal of Molecular Neuroscience, 2011, 45, 425-431.	2.3	107
40	Cell-Mediated Neuroprotection in a Mouse Model of Human Tauopathy. Journal of Neuroscience, 2010, 30, 9973-9983.	3.6	106
41	Assignment of Human Î±-Synuclein (SNCA) and Î²-Synuclein (SNCB) Genes to Chromosomes 4q21 and 5q35. Genomics, 1995, 27, 379-381.	2.9	105
42	Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology. Experimental Neurology, 2015, 265, 48-58.	4.1	104
43	Î±-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons. Journal of Cell Science, 2015, 128, 2231-2243.	2.0	99
44	Anti-amyloid Compounds Inhibit Î±-Synuclein Aggregation Induced by Protein Misfolding Cyclic Amplification (PMCA). Journal of Biological Chemistry, 2014, 289, 11897-11905.	3.4	83
45	Astrocytes in mouse models of tauopathies acquire early deficits and lose neurosupportive functions. Acta Neuropathologica Communications, 2017, 5, 89.	5.2	83
46	Neurodegeneration and the ordered assembly of Î±-synuclein. Cell and Tissue Research, 2018, 373, 137-148.	2.9	79
47	Depopulation of dense Î±-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinsonâ€™s disease model. Acta Neuropathologica, 2019, 138, 575-595.	7.7	79
48	Alpha-synuclein dysfunction in Lewy body diseases. Movement Disorders, 2005, 20, S37-S44.	3.9	76
49	Early behavioural markers of disease in P301S tau transgenic mice. Behavioural Brain Research, 2010, 208, 250-257.	2.2	76
50	Presence of Reactive Microglia and Neuroinflammatory Mediators in a Case of Frontotemporal Dementia with P301S Mutation. Neurodegenerative Diseases, 2011, 8, 221-229.	1.4	74
51	Frontotemporal Dementia with Tau Pathology. Neurodegenerative Diseases, 2007, 4, 236-253.	1.4	69
52	Redistribution of DAT/Î±-Synuclein Complexes Visualized by â€œIn Situâ€•Proximity Ligation Assay in Transgenic Mice Modelling Early Parkinson's Disease. PLoS ONE, 2011, 6, e27959.	2.5	62
53	Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra. Experimental Neurology, 2013, 248, 541-545.	4.1	60
54	Microglia become hypofunctional and release metalloproteases and tau seeds when phagocytosing live neurons with P301S tau aggregates. Science Advances, 2021, 7, eabg4980.	10.3	60

#	Article	IF	Citations
55	From genetics to pathology: tau and aâ€“synuclein assemblies in neurodegenerative diseases. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 213-227.	4.0	58
56	Reduced Axonal Transport and Increased Excitotoxic Retinal Ganglion Cell Degeneration in Mice Transgenic for Human Mutant P301S Tau. PLoS ONE, 2012, 7, e34724.	2.5	56
57	Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. Movement Disorders, 2012, 27, 312-315.	3.9	56
58	Tau-Driven Neuronal and Neurotrophic Dysfunction in a Mouse Model of Early Tauopathy. Journal of Neuroscience, 2016, 36, 2086-2100.	3.6	56
59	Tau Gene Mutations in Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 (FTDPâ€17): Their Relevance for Understanding the Neurogenerative Process. Annals of the New York Academy of Sciences, 2000, 920, 74-83.	3.8	54
60	Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology. International Journal of Molecular Sciences, 2019, 20, 141.	4.1	52
61	Antibody recognizing 4-sulfated chondroitin sulfate proteoglycans restores memory in tauopathy-induced neurodegeneration. Neurobiology of Aging, 2017, 59, 197-209.	3.1	49
62	Association Between Tau H2 Haplotype and Age at Onset in Frontotemporal Dementia. Archives of Neurology, 2005, 62, 1419.	4.5	40
63	A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Annals of Neurology, 2000, 48, 939-943.	5.3	40
64	Tau and Î±-Synuclein Inclusions in a Case of Familial Frontotemporal Dementia and Progressive Aphasia. Journal of Neuropathology and Experimental Neurology, 2005, 64, 245-253.	1.7	39
65	Tau Protein in Frontotemporal Dementia Linked to Chromosome 3 (FTD-3). Journal of Neuropathology and Experimental Neurology, 2003, 62, 878-882.	1.7	36
66	Tau Pathology is PresentIn Vivoand DevelopsIn Vitroin Sensory Neurons from Human P301S Tau Transgenic Mice: A System for Screening Drugs against Tauopathies. Journal of Neuroscience, 2013, 33, 18175-18189.	3.6	36
67	Tau Protein in Familial and Sporadic Diseases. NeuroMolecular Medicine, 2003, 4, 37-48.	3.4	35
68	Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis. Acta Neuropathologica, 2009, 117, 583-589.	7.7	35
69	The fluorescent pentameric oligothiophene pFTAA identifies filamentous tau in live neurons cultured from adult P301S tau mice. Frontiers in Neuroscience, 2015, 9, 184.	2.8	34
70	Human Stem Cell-Derived Neurons: A System to Study Human Tau Function and Dysfunction. PLoS ONE, 2010, 5, e13947.	2.5	31
71	The microglial P2Y6 receptor mediates neuronal loss and memory deficits in neurodegeneration. Cell Reports, 2021, 37, 110148.	6.4	31
72	Progress in Hereditary Tauopathies: A Mutation in the Tau Gene (G389R) Causes a Pick Diseaseâ€like Syndrome. Annals of the New York Academy of Sciences, 2000, 920, 52-62.	3.8	30

#	Article	IF	Citations
73	Abnormal tau phosphorylation in primary progressive multiple sclerosis. Acta Neuropathologica, 2010, 119, 591-600.	7.7	30
74	Parkinson's disease as a member of Prion-like disorders. Virus Research, 2015, 207, 38-46.	2.2	30
75	Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure. Neurochemistry International, 2015, 85-86, 14-23.	3.8	30
76	The novel MAPT mutation K298E: mechanisms of mutant tau toxicity, brain pathology and tau expression in induced fibroblast-derived neurons. Acta Neuropathologica, 2014, 127, 283-295.	7.7	29
77	Super-resolution imaging reveals Î±-synuclein seeded aggregation in SH-SY5Y cells. Communications Biology, 2021, 4, 613.	4.4	26
78	Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial. EBioMedicine, 2022, 80, 104021.	6.1	26
79	Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate. Neurobiology of Disease, 2020, 138, 104789.	4.4	19
80	Mutations in the tau gene (MAPT) in FTDP-17: The family with Multiple System Tauopathy with Presenile Dementia (MSTD). Journal of Alzheimer's Disease, 2006, 9, 373-380.	2.6	18
81	Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation. Glia, 2016, 64, 457-471.	4.9	16
82	CSPÎ± reduces aggregates and rescues striatal dopamine release in Î±-synuclein transgenic mice. Brain, 2021, 144, 1661-1669.	7.6	14
83	pFTAA - a high affinity oligothiophene probe that detects filamentous tau in vivo and in cultured neurons. Neural Regeneration Research, 2015, 10, 1746.	3.0	14
84	Nonâ€Alzheimer Degenerative Dementias. Brain Pathology, 1998, 8, 295-297.	4.1	13
85	Compound heterozygosity of 2 novel MAPT mutations in frontotemporal dementia. Neurobiology of Aging, 2011, 32, 757.e1-757.e11.	3.1	13
86	Progressive tauopathy in P301S tau transgenic mice is associated with a functional deficit of the olfactory system. European Journal of Neuroscience, 2016, 44, 2396-2403.	2.6	12
87	Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype. Molecular Therapy, 2022, 30, 1465-1483.	8.2	9
88	Release of growth factors by neuronal precursor cells as a treatment for diseases with tau pathology. Archives Italiennes De Biologie, 2011, 149, 215-23.	0.4	9
89	Focal expression of adeno-associated viral-mutant tau induces widespread impairment in an APP mouse model. Neurobiology of Aging, 2013, 34, 1355-1368.	3.1	8
90	Tau aggregation and its relation to selected forms of neuronal cell death. Essays in Biochemistry, 2021, 65, 847-857.	4.7	7

#	Article	IF	Citations
91	A novel mutation at position +12 in the intron following Exon 10 of the tau gene in familial frontotemporal dementia (FTDâ€Kumamoto). Annals of Neurology, 2000, 47, 422-429.	5.3	6
92	Synucleinopathies and Tauopathies. , 2012, , 829-843.		5
93	Editorial: Tau Pathology in Neurological Disorders. Frontiers in Neurology, 2021, 12, 754669.	2.4	2
94	TAU GENE MUTATIONS IN FRONTOTEMPORAL DEMENTIA AND PARKINSONISM LINKED TO CHROMOSOME 17. , 2003, , .		0
95	The neurobiology of the tauopathies. , 2003, , 245-261.		0
96	Molecular Biology of Lewy Body Formation. Advances in Behavioral Biology, 2002, , 483-489.	0.2	0